NCT01294579 2018-08-09
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Novartis
Phase 2 Completed
Novartis
University of California, San Diego
Novartis
Brno University Hospital
GlaxoSmithKline
Nevada Cancer Institute